Eugit Therapeutics
Enabling Tissue Targeting of Therapies
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
- Website
- eugittx.com
- City
- San Francisco
- Country
- United States
- YC batch
- Summer 2022
- Team
- 2 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in San Francisco
Innovaccer$1.3bn
Indian digital healthcare company.
Thatch$1bn
Health benefits. Valued at $1bn (September 2026).
Chan Zuckerberg BiohubLab
Nonprofit research network building virtual cell models.
AthelasHiring
Extensible, Integrated Technology that Simplifies Health Systems
ClipboardHiring
Every shift, Covered.
Benchling
Unlocking the power of biotech with modern software for modern science
Claim this profile
Free and instant: prove you run eugittx.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Eugit Therapeutics across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Eugit Therapeutics's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
